PFS

Viktig sikkerhets- og forskrivningsinformasjon

Efficacy data - PFS

PFS in Patients with PD-L1 <1 %

Opdualag more than doubled median Progression Free Survival (PFS) vs nivolumab
monotherapy patients with PD-L1 <1% in treatment – naïve, advanced melanoma¹

Median follow-up 17.8 months¹

Reference:

Opdualag SmPC

At the 33.8-month median follow-up
PFS in Intention to Treat (ITT) population^1,*

Progression free survival (PFS) Opdualag vs nivolumab^{1 *}

^*ITT-population. EU approved indication: PD-L1 <1%.

Reference:

Tawbi HA, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 (2024). J Clin Oncol. 2024 Dec 13:JCO2401124. https://doi.org/10.1200/JCO.24.01124.

1425-NO-2500004 February 2025

We refer to the SmPC for full information on Opdualag^®

Efficacy data - PFS

At the 33.8-month median follow-up PFS in Intention to Treat (ITT) population1,*

At the 33.8-month median follow-up
PFS in Intention to Treat (ITT) population^1,*